Scientists Turn Plastic Bottles Into Parkinson's Medicine Using Engineered Bacteria

Plastic Waste Gets a Second Life as Medicine

Scientists at the University of Edinburgh have achieved a remarkable breakthrough: turning discarded plastic bottles into a key medication for Parkinson's disease using engineered bacteria.

The research, published in Nature Sustainability, demonstrates how specially engineered E. coli bacteria can convert polyethylene terephthalate, the plastic known as PET found in everyday food and drink packaging, into L-DOPA, the primary treatment for Parkinson's disease. It marks the first time a biological process has been used to transform plastic waste into a therapeutic for a neurological condition.

How It Works

The process involves two stages. First, PET waste is broken down into its chemical building blocks, specifically terephthalic acid. The engineered bacteria then convert this compound into L-DOPA through a series of biological reactions. The research team overcame two key technical challenges: getting the bacteria to efficiently import the substrate, and preventing feedback inhibition during the conversion process.

Why It Matters

With roughly fifty million tonnes of PET produced globally each year and existing recycling methods remaining inefficient, the technique offers a sustainable alternative to traditional pharmaceutical manufacturing, which relies heavily on fossil fuels. Rather than ending up in landfill or being incinerated, waste plastic becomes a valuable carbon source for producing medicine.

What Comes Next

The research was conducted at the university's fourteen million pound Carbon-Loop Sustainable Biomanufacturing Hub. Having demonstrated L-DOPA production at preparative scale, the team plans to optimise the process for industrial application, focusing on scalability and further assessing environmental and economic performance. The technology could also extend to producing flavourings, fragrances, cosmetics, and industrial chemicals from waste plastic.